Screener
Janux Therapeutics JANX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
The source filing: Janux Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212146
FAQ
- What is Janux Therapeutics's free cash flow?
- Janux Therapeutics (JANX) reported free cash flow of -$12.61M in Q1 2026.
- How has Janux Therapeutics's free cash flow changed year-over-year?
- Janux Therapeutics's free cash flow increased by 27.5% year-over-year, from -$17.4M to -$12.61M.
- What is the long-term trend for Janux Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Janux Therapeutics's free cash flow has grown at a 45.7% compound annual growth rate (CAGR), from -$18.46M to -$83.28M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Janux Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude